Adjuvant and neoadjuvant therapy for early stage non-small cell lung cancer

K M Pisters

doi:10.1016/s0093-7754(01)90056-9

Adjuvant and neoadjuvant therapy for early stage non-small cell lung cancer

Semin Oncol. 2001 Aug;28(4 Suppl 14):23-8. doi: 10.1016/s0093-7754(01)90056-9.

Author

K M Pisters¹

Affiliation

¹ Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030-4009, USA.

PMID: 11605180
DOI: 10.1016/s0093-7754(01)90056-9

Abstract

Lung cancer is the number one cause of cancer-related death in both men and women in the United States. Non-small cell lung cancer accounts for approximately 85% of these cases. Despite complete resection, long-term survival for patients with operable disease remains poor. Studies exploring postoperative chemotherapy have not shown improved survival. Preoperative chemotherapy has shown promise in stage III disease and is currently under investigation for patients with early stage non-small cell lung cancer.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antineoplastic Agents / therapeutic use
Carcinoma, Non-Small-Cell Lung / therapy*
Clinical Trials as Topic
Combined Modality Therapy
Humans
Lung Neoplasms / therapy*
Neoadjuvant Therapy

Substances

Antineoplastic Agents